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Background: The recent STICH trial suggested lack of prognostic benefit of revascularization of myocardium deemed viable by standard 
techniques. We sought the impact of completeness of revascularization and medical therapy in relation to jeopardized myocardium in patients with 
left ventricular (LV) dysfunction secondary to known or suspected coronary artery disease.
Methods: 661 consecutive patients (age 65±12, 23% female, mean LVEF 31±12%) underwent fluorodeoxyglucose positron emission tomography 
(PET/FDG). The extent of perfusion defects and metabolism-perfusion mismatch was measured with an automated quantitative method. 
Revascularization was performed within 90 days of PET in 222 patients (34%), and a propensity score reflecting this was included as a covariate to 
account for indication bias. Complete revascularization was performed in 121 patients, 103 underwent incomplete revascularization and 439 (66%) 
were treated medically.
Results: During a mean follow-up of 2.8 ± 1.4 years, there were 218 (33%) deaths. Complete revascularization was associated with lower rate of 
death (HR 0.64 [95%CI 0.40-0.97]; p=0.038). Increasing amounts of jeopardized myocardium were associated with increasing benefit of complete 
revascularization but less benefit of incomplete revascularization as compared to medical therapy alone. At ≥25% of jeopardized myocardium, 
there was significant survival benefit with complete revascularization (HR 0.64 [95%CI, 0.41-0.99]; p=0.049). Incomplete revascularization may be 
associated with harm in association with more extensive jeopardized myocardium.
Conclusions: Among patients with ischemic cardiomyopathy, there is progressive benefit of complete revascularization with the increasing 
amounts of jeopardized myocardium. Complete revascularization is associated with improved survival in patients with extensive jeopardized 
myocardium.
